0RK9 Stock Overview
A research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Alligator Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.57 |
| 52 Week High | SEK 1.51 |
| 52 Week Low | SEK 0.50 |
| Beta | 1.48 |
| 11 Month Change | -52.75% |
| 3 Month Change | n/a |
| 1 Year Change | 34.92% |
| 33 Year Change | -77.44% |
| 5 Year Change | -95.23% |
| Change since IPO | -98.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RK9 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -15.6% | 2.0% | 1.7% |
| 1Y | 34.9% | -17.5% | 8.3% |
Return vs Industry: 0RK9 exceeded the UK Biotechs industry which returned -17.5% over the past year.
Return vs Market: 0RK9 exceeded the UK Market which returned 8.3% over the past year.
Price Volatility
| 0RK9 volatility | |
|---|---|
| 0RK9 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RK9's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0RK9's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 47 | Søren Bregenholt | www.alligatorbioscience.se |
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG
Alligator Bioscience AB (publ) Fundamentals Summary
| 0RK9 fundamental statistics | |
|---|---|
| Market cap | SEK 399.49m |
| Earnings (TTM) | -SEK 248.30m |
| Revenue (TTM) | SEK 27.77m |
14.4x
P/S Ratio-1.6x
P/E RatioIs 0RK9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RK9 income statement (TTM) | |
|---|---|
| Revenue | SEK 27.77m |
| Cost of Revenue | SEK 182.11m |
| Gross Profit | -SEK 154.33m |
| Other Expenses | SEK 93.97m |
| Earnings | -SEK 248.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -555.68% |
| Net Profit Margin | -894.02% |
| Debt/Equity Ratio | 0% |
How did 0RK9 perform over the long term?
See historical performance and comparison